Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elanco Animal Health Incorporated (NYSE: ELAN) SEC filings page on Stock Titan provides organized access to the company’s U.S. regulatory disclosures. As an Indiana-incorporated public company in the pharmaceutical preparation manufacturing industry, Elanco files reports with the Securities and Exchange Commission under Commission File Number 001-38661.
Through this page, readers can review current and historical Forms 8-K and, when available, annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials. Elanco’s recent Form 8-K filings illustrate the range of topics covered in its SEC disclosures, including quarterly financial results and guidance, restructuring plans and workforce changes, amendments to credit agreements and receivables facilities, and participation in major investor events such as its Investor Day and healthcare conferences.
These filings provide detail on Elanco’s financial condition, capital structure and risk factors, as well as material contracts and strategic initiatives. For example, recent 8-Ks describe the Elanco Ascend restructuring program, expected cost savings, facility changes, and refinancing of term loan facilities, along with updates on leverage targets and cash flow expectations. Other filings outline amendments to securitization and credit agreements that affect the company’s direct financial obligations.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the significance of each filing. Investors can use the ELAN filings page to monitor new 8-Ks, as well as future 10-K and 10-Q reports, and to track how management’s strategic, financial and operational decisions are reflected in official SEC documents.
Elanco Animal Health Inc. (ELAN) reported insider awards to Executive Vice President and Chief Financial Officer Robert M. VanHimbergen. The Form 4 discloses a grant of 109,857 restricted stock units that vest in three equal tranches on July 7, 2026, July 7, 2027, and July 7, 2028. The filing also shows a grant of 53,869 employee stock options with an exercise price of $20.80, exercisable beginning in the same three-tranche schedule and expiring on October 1, 2035. Both holdings are reported as direct ownership following the transactions. The Form 4 was signed by an attorney-in-fact on behalf of Mr. VanHimbergen and lists the transaction date as October 1, 2025.
Jeffrey N. Simmons, President, CEO and Director of Elanco Animal Health Inc (ELAN), reported an acquisition of 144.2313 deferred stock units on 09/19/2025. Each deferred stock unit represents the right to one share of common stock or the cash equivalent and settles in cash or shares under the company’s Executive Deferral and Stock Match Plan. The reported transaction used transaction code A (acquisition) at an indicated underlying price of $19.20 per share, and following the transaction Mr. Simmons beneficially owns 17,836.142 shares directly. The Form 4 was signed on behalf of Mr. Simmons by Amy C. Seidel as attorney-in-fact on 09/23/2025.
Rajeev A. Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation at Elanco Animal Health Inc. (ELAN), acquired 73.6781 deferred stock units on 09/19/2025 under the companys Executive Deferral and Stock Match Plan. Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent, and such units settle in cash or shares following termination of employment or in a specified future year. After the reported transaction Mr. Modi beneficially owned 6,964.7245 units (directly).
The units were reported with an indicated price of $19.20 per underlying share. The filing was signed by an attorney-in-fact on behalf of Mr. Modi and notes his officer role; no other material transactions or additional context are included.
Jeffrey N. Simmons, President, CEO and Director of Elanco Animal Health Inc. (ELAN), acquired 150.2572 deferred stock units on 09/05/2025 at an attributable price of $18.43 each. Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent, and these units settle in cash or shares following termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Following this transaction, Mr. Simmons' beneficial ownership is reported as 17,691.9107 shares (direct). The Form 4 was signed by an attorney-in-fact on 09/09/2025. No other cash purchases, sales, or derivative exercises are reported in this filing.
Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation at Elanco Animal Health Inc. (ELAN), reported a Section 16 transaction on 09/05/2025. The filing records an acquisition of 76.7564 deferred stock units (DSUs) at an indicated price of $18.43 per unit. Each DSU represents the right to receive one share of common stock or the cash equivalent and DSUs settle in cash or shares following termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan. The report shows 6,891.0464 shares beneficially owned following the transaction. The Form 4 was signed by Amy C. Seidel as attorney-in-fact on 09/09/2025.
Jeffrey N. Simmons, President, CEO and Director of Elanco Animal Health Inc. (ELAN), reported an acquisition on 08/22/2025 of 154.6198 deferred stock units. Each deferred stock unit represents the right to one share of common stock or a cash equivalent and the units were priced at $17.91 per underlying share for reporting purposes. Following the reported transaction, Mr. Simmons beneficially owned 17,541.6535 shares (or economic equivalents) of Elanco common stock. The deferred stock units will settle in cash or shares following termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan. The Form 4 was signed on behalf of Mr. Simmons by an attorney-in-fact on 08/26/2025.
Elanco Animal Health insider transaction: The Form 4 reports that Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation, was granted 78.9849 deferred stock units on 08/22/2025. Each deferred stock unit represents the right to receive one share of Elanco common stock or a cash equivalent. The filing shows an exercise/reference price of $17.91 and indicates Mr. Modi beneficially owns 6,814.29 shares (or units) following the reported transaction. The deferred units will settle in cash or shares following termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health Inc.'s President, CEO and Director Jeffrey N. Simmons acquired 166.1212 deferred stock units on 08/08/2025 under the company's Executive Deferral and Stock Match Plan. Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent. After the reported acquisition, Mr. Simmons beneficially owns 17,387.0337 common stock-equivalent units on a direct basis. The deferred units may settle in cash or shares following termination of employment or during a specified future year.
This Form 4, filed for Elanco Animal Health Inc. (ELAN), reports that Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation, had a transaction dated 08/08/2025. The filing shows acquisition of deferred stock units with a recorded amount of 6,735.3051 (displayed in the form) and a price field showing $16.67. The form notes each deferred stock unit represents the right to receive one share of common stock or the cash equivalent and that units settle in cash or shares following termination of employment or during a specified future year under the Executive Deferral and Stock Match Plan. The filing was signed by Amy C. Seidel as attorney-in-fact on 08/12/2025 and was filed by one reporting person.
Elanco Animal Health (ELAN) reported a proposed sale of 49,333 shares of common stock through UBS on the NYSE with an aggregate market value of $830,000, representing approximately 0.01% of the 496,646,504 shares outstanding. The filing lists the acquisition history: 1,536 shares on 12/03/2020, 16,738 shares on 02/22/2021, and 31,059 shares on 02/22/2022, all identified as stock awards.
The notice indicates no securities sold in the past three months and includes the signatory's representation that they do not know any material nonpublic information about the issuer. The form references Rule 144 procedures and mentions Rule 10b5-1 plan disclosure but does not provide a plan adoption or instruction date.
FAQ
What is the current stock price of Elanco Animal Health (ELAN)?
What is the market cap of Elanco Animal Health (ELAN)?
